Alexion Pharmaceuticals, Inc. (ALXN) Holdings Raised by AMP Capital Investors Ltd

AMP Capital Investors Ltd raised its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 11.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 88,361 shares of the biopharmaceutical company’s stock after purchasing an additional 9,427 shares during the period. AMP Capital Investors Ltd’s holdings in Alexion Pharmaceuticals were worth $12,396,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in ALXN. Russell Investments Group Ltd. boosted its holdings in shares of Alexion Pharmaceuticals by 22.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 35,588 shares of the biopharmaceutical company’s stock valued at $4,331,000 after buying an additional 6,438 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at $160,000. NGAM Advisors L.P. boosted its holdings in shares of Alexion Pharmaceuticals by 24.5% in the 2nd quarter. NGAM Advisors L.P. now owns 16,953 shares of the biopharmaceutical company’s stock valued at $2,063,000 after buying an additional 3,335 shares in the last quarter. Global X Management Co. LLC boosted its stake in Alexion Pharmaceuticals by 37.5% during the 2nd quarter. Global X Management Co. LLC now owns 2,703 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 737 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in Alexion Pharmaceuticals by 14.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 795,572 shares of the biopharmaceutical company’s stock worth $96,798,000 after purchasing an additional 97,659 shares during the period. 94.16% of the stock is currently owned by institutional investors.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $114.46 on Monday. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a market cap of $25,570.00, a price-to-earnings ratio of 23.41, a PEG ratio of 1.24 and a beta of 1.18. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter last year, the business earned $1.23 EPS. The business’s revenue was up 7.5% on a year-over-year basis. equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.

A number of analysts recently weighed in on the stock. Leerink Swann reiterated a “buy” rating and set a $169.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, December 6th. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Royal Bank Of Canada increased their price target on shares of Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Finally, Stifel Nicolaus decreased their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research note on Tuesday, October 24th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $154.49.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://weekherald.com/2017/12/11/alexion-pharmaceuticals-inc-alxn-holdings-raised-by-amp-capital-investors-ltd.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply